Testing CB03-154 for adults with ALS
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You should have been diagnosed with ALS within the last 24 months.
- Your lung function (FVC) must be above 80% of what's expected for your age and size.
- You must be able to swallow pills at the start of the study.
- If you take riluzole or edaravone, your dose must be stable and you should keep taking it during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new medicines (galunisertib and nerandomilast) together in people with a specific type of ALS. The combination may slow down the damage in the nervous system, and the trial is looking at whether it's safe and helps.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This trial tests whether FB1006 is safe and works better than usual care for treating amyotrophic lateral sclerosis (ALS). It focuses on people with relatively early ALS and good breathing function.
This study tests a new medicine called BIIB147 to see if it is safe and to learn how it affects people with ALS. It may help slow the progression of the disease.
This study tests an experimental drug called AMX0114 for people recently diagnosed with ALS. It is an early-phase trial to see if the drug is safe and how it affects the body.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.